Quantcast

Latest Parkinson's disease Stories

2014-05-16 23:07:47

Transparency Market Research published a new report "Deep Brain Stimulation Devices Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to its report store. Browse full report: http://www.transparencymarketresearch.com/deep-brain-stimulator-market.html. Albany, New York (PRWEB) May 16, 2014 A rise in ageing population has been found to be the major causative factor for development of Parkinson’s disease. Parkinson’s disease is the...

2014-05-07 09:50:08

Follow-up study published in the Journal of Parkinson's Disease supports an earlier 'proof of concept' trial A follow-up study of patients with Parkinson's disease (PD) who participated in an earlier "proof of concept" clinical trial using exenatide showed that improvements persisted twelve months after discontinuing exenatide therapy. These data provide strong encouragement for the further study of this drug in patients with PD, report researchers in the Journal of Parkinson's Disease....

2014-04-30 23:10:24

Vick is one of less than 100 clinicians across the state, and one of 1,600 worldwide, to earn this certification, according to LSVT Global. Franklin, Va. (PRWEB) April 30, 2014 If you ask Tracey Vick, she’ll tell you she decided to pursue a career in physical therapy after helping her grandfather to his clinical appointments following his stroke. Today, Tidewater Physical Therapy is pleased to announce that Vick, a Physical Therapy Assistant who works with patients in the Franklin, Va....

2014-04-30 08:33:57

Positive Clinician-Reported Patient Assessments Consistent with Earlier Findings Reported with ADS-5102 EMERYVILLE, Calif., April 30, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a specialty pharmaceutical company, today presented data on the safety and efficacy of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID), a serious movement disorder associated with Parkinson's disease treatment. The data, from Adamas' Phase 2/3 EASED study, included...

2014-04-29 08:36:49

GULF SHORES, Ala., April 29, 2014 /PRNewswire/ -- If successful, Neuralgene's (http://www.neuralgene.com) PRCN-323 treatment could significantly change the prognosis for everyone with the rare genetic disorder known as adrenoleukodystrophy, or ALD. The biotech company has recently celebrated a series of early successes in the treatment of other neurological conditions like ALS (Lou Gehrig's disease). Founder and CEO Jason Williams, M.D., believes his team is on the path toward a cure...

2014-04-28 16:27:09

PHILADELPHIA, April 28, 2014 /PRNewswire-USNewswire/ -- A review by the American Academy of Neurology of available scientific research on the use of medical marijuana in brain diseases finds certain forms of medical marijuana can help treat some symptoms of multiple sclerosis (MS), but do not appear to be helpful in treating drug-induced (levodopa) movements in Parkinson's disease. Not enough evidence was found to show if medical marijuana is helpful in treating motor problems in...

2014-04-28 12:27:49

NEW YORK, April 28, 2014 /PRNewswire-USNewswire/ -- Founder Michael J. Fox; CEO Todd Sherer, PhD; and Co-Founder and Executive Vice Chairman Deborah W. Brooks of The Michael J. Fox Foundation for Parkinson's Research (MJFF) are featured on the cover of the inaugural issue of Clinical Researcher, the journal of the Association of Clinical Research Professionals. http://photos.prnewswire.com/prnvar/20140425/79262 The April 2014 cover story, authored by Sherer and other MJFF staff, is...

2014-04-28 08:33:12

EU support boosts development of therapeutic vaccines against Parkinson's and Multiple System Atrophy. AFFiRiS leads consortium. VIENNA, April 28, 2014 /PRNewswire/ -- An international consortium of top European research teams has received significant EU funding for the development of therapeutic vaccines against Parkinson's Disease (PD) and Multiple System Atrophy (MSA). Led by the Austrian biotech company AFFiRiS AG, the consortium will use a novel tandem strategy to advance...

Existing Cochlear Technology Used To Re-grow Auditory Nerves
2014-04-24 03:24:49

[ Watch The Video: Bionic Ear Delivers DNA To Regrow Auditory Nerve Cells ] University of New South Wales Researchers at UNSW Australia have for the first time used electrical pulses delivered from a cochlear implant to deliver gene therapy, thereby successfully regrowing auditory nerves. The research also heralds a possible new way of treating a range of neurological disorders, including Parkinson's disease, and psychiatric conditions such as depression through this novel way...

2014-04-23 16:30:11

EMERYVILLE, Calif., April 23, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a specialty pharmaceutical company, today announced a poster presentation at the American Academy of Neurology (AAN) 66(th) Annual Meeting, April 26 to May 3, 2014, in Philadelphia, PA. http://photos.prnewswire.com/prnvar/20130618/LA33709LOGO The poster (4009), is titled, "Safety and Efficacy Study of ADS-5102 (amantadine HCl) extended release capsules in Levodopa-Induced Dyskinesia...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related